AbbVie, J&J to add proprietary data to AI protein model in bid to accelerate drug discovery
Posted:
Life sciences data company Apheris on Thursday announced an effort to boost the capabilities of protein AI models by uniting several pharmaceutical companies’ proprietary data. Apheris’ consortium of pharma companies is partnering with OpenFold3 — Columbia professor Mohammed AlQuraishi’s open-source dupe of AlphaFold3 — to train the model on AbbVie and Johnson & Johnson’s vast stores of structural data. The collaboration will focus on structures relevant to drug discovery, such as small molecule-protein and antibody-antigen interactions.
Akeso, a Chinese biotech that made headlines for beating Merck’s Keytruda in a head-to-head trial, won approval in China this week for the therapy, a company spokesperson confirmed to STAT. New data show early hints of the medicine improving patient…
From detecting TB, cancer, and heart attacks to diagnosing patients with strokes and diabetes, Artificial Intelligence (AI) is redefining the healthcare system across the world. Currently, more than 90% of hospitals and healthcare systems have implemented an AI or automation strategy,…
Attendees
Sponsors and Exhibitors
AI In Healthcare: A Virtual Course
Contact us